Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis
暂无分享,去创建一个
[1] D. Menzies,et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. , 2008, American journal of respiratory and critical care medicine.
[2] S. Glickman,et al. A Portfolio Model of Drug Development for Tuberculosis , 2006, Science.
[3] J. Bayona,et al. Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible , 2008, PloS one.
[4] D. van Soolingen,et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[5] Ross Upshur,et al. XDR-TB in South Africa: No Time for Denial or Complacency , 2007, PLoS medicine.
[6] A. Khomenko,et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.
[7] G W Comstock,et al. Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.
[8] M. Morrow,et al. Long term efficacy of DOTS regimens for tuberculosis: systematic review , 2008, BMJ : British Medical Journal.
[9] M. Borgdorff,et al. Beijing/W Genotype Mycobacterium tuberculosis and Drug Resistance , 2006, Emerging infectious diseases.
[10] L. Tanoue. Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis , 2009 .
[11] Mehran Hosseini,et al. Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.
[12] Fernando Baquero,et al. Predicting antibiotic resistance , 2007, Nature Reviews Microbiology.
[13] Yong Soo Choi,et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] C. Dye,et al. Will tuberculosis become resistant to all antibiotics? , 2001, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[15] C. Garzelli. Beijing/W Genotype Mycobacterium tuberculosis and Drug Resistance , 2006 .
[16] T. Chou,et al. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance , 2004, Nature Medicine.
[17] M. Uplekar,et al. WHO's new Stop TB Strategy , 2006, The Lancet.
[18] J. Furin. The clinical management of drug-resistant tuberculosis , 2007, Current opinion in pulmonary medicine.
[19] B G Williams,et al. Criteria for the control of drug-resistant tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[20] Christopher Dye,et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy , 1998, The Lancet.
[21] J. Hansan. The end of an era. , 1996, Journal of aging & social policy.
[22] S. Niemann,et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia , 2005, Respiratory research.
[23] C. Dye,et al. Can DOTS control multidrug-resistant tuberculosis? , 2005, The Lancet.
[24] K. Floyd,et al. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. , 2002, Bulletin of the World Health Organization.
[25] T. Holtz,et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study , 2005, The Lancet.
[26] S. Gillespie,et al. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). , 2008, Tuberculosis.
[27] R. Koenig. In South Africa, XDR TB and HIV Prove a Deadly Combination , 2008, Science.
[28] M. Spigelman,et al. New tuberculosis therapeutics: a growing pipeline. , 2007, The Journal of infectious diseases.
[29] C. Dye,et al. Worldwide incidence of multidrug-resistant tuberculosis. , 2002, The Journal of infectious diseases.
[30] N. Schluger,et al. Underreported Threat of Multidrug-Resistant Tuberculosis in Africa , 2008, Emerging infectious diseases.
[31] T. Cohen,et al. Challenges in estimating the total burden of drug-resistant tuberculosis. , 2008, American journal of respiratory and critical care medicine.
[32] Sonya S. Shin,et al. Epidemiology and Treatment of Multidrug Resistant Tuberculosis , 2008, Seminars in respiratory and critical care medicine.
[33] P. Deschavanne,et al. Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. , 2007, Molecular biology and evolution.
[34] Pradeep Mitra Ecspe,et al. REPORT NO , 2001 .
[35] M. Edwards. Evidence , 2004, The Lancet.
[36] P. V. van Helden,et al. Beijing and Haarlem Genotypes Are Overrepresented among Children with Drug-Resistant Tuberculosis in the Western Cape Province of South Africa , 2006, Journal of Clinical Microbiology.
[37] J. Yudkin,et al. Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[38] D. van Soolingen,et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes , 2003, Clinical and experimental immunology.
[39] Ted Cohen,et al. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness , 2004, Nature Medicine.
[40] J. Farrar,et al. The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosis , 2008, PLoS pathogens.
[41] D. Andersson,et al. Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis , 2004, Antimicrobial Agents and Chemotherapy.
[42] Roger Finch,et al. Lack of development of new antimicrobial drugs: a potential serious threat to public health. , 2005, The Lancet. Infectious diseases.
[43] D. Caugant,et al. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. , 2004, FEMS immunology and medical microbiology.
[44] E. Nardell,et al. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. , 2007, The Journal of infectious diseases.
[45] G. Bai,et al. Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.
[46] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[47] P. V. van Helden,et al. Spread of a Low-Fitness Drug-Resistant Mycobacterium tuberculosis Strain in a Setting of High Human Immunodeficiency Virus Prevalence , 2008, Journal of Clinical Microbiology.
[48] Sonya S. Shin,et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study , 2008, The Lancet.
[49] S. Schrag,et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study , 2008, The Lancet.
[50] A. Chaiprasert,et al. Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[51] B. Cowling,et al. Age-period-cohort analysis of tuberculosis notifications in Hong Kong , 2006 .
[52] Neel R Gandhi,et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.
[53] Ted Cohen,et al. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.
[54] S. Blower,et al. Predicting the future of XDR tuberculosis. , 2007, The Lancet. Infectious diseases.
[55] C. D. Long,et al. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis , 2006, Science.
[56] M. Donald Cave,et al. Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.
[57] C. Dye,et al. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[58] Patrick Deschavanne,et al. Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis. , 2006, Molecular biology and evolution.
[59] A. W. Sturm,et al. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. , 2007, Clinical Infectious Diseases.
[60] C. Tam,et al. Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005 , 2007, Thorax.
[61] E. Chan,et al. Treatment outcomes in extensively resistant tuberculosis. , 2008, The New England journal of medicine.
[62] M. Raviglione. XDR-TB: entering the post-antibiotic era? , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[63] K. Derbyshire,et al. IS6110, a Mycobacterium tuberculosis Complex-Specific Insertion Sequence, Is Also Present in the Genome of Mycobacterium smegmatis, Suggestive of Lateral Gene Transfer among Mycobacterial Species , 2008, Journal of bacteriology.
[64] J. Mukherjee,et al. Multidrug-resistant Tuberculosis Management in Resource-limited Settings , 2006, Emerging infectious diseases.
[65] C. Dye,et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. , 2001, The Journal of infectious diseases.
[66] Stefan Niemann,et al. Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance , 2006, PLoS medicine.
[67] F. Cobelens,et al. Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda , 2008, PLoS medicine.
[68] J. Bayona,et al. Long-term Follow-up for Multidrug-resistant Tuberculosis , 2006, Emerging infectious diseases.
[69] E. Nardell. Environmental infection control of tuberculosis. , 2003, Seminars in respiratory infections.
[70] S. Niemann,et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] Brian G. Williams,et al. Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.
[72] P. Small,et al. Does DOTS work in populations with drug-resistant tuberculosis? , 2005, The Lancet.